Amplify Energy Corp
Change company Symbol lookup
Select an option...
AMPY Amplify Energy Corp
ABBV Abbvie Inc
BABA Alibaba Group Holding Ltd
OBMP OncBioMune Pharmaceuticals Inc
AVNW Aviat Networks Inc
JEPI JPMorgan Equity Premium Income ETF
VOLAF Volvo AB
AGNC Agnc Investment Corp
GME GameStop Corp
HMNKF HMS Networks AB
Go

Energy : Oil, Gas & Consumable Fuels | Small Cap Value
Company profile

Amplify Energy Corp, formerly Midstates Petroleum Company, Inc., is an independent oil and natural gas company. The Company is engaged in the acquisition, development, exploration and production of oil and natural gas properties. Its operations are focused in the Rockies, offshore California, Oklahoma, East Texas / North Louisiana and South Texas. It has approximately 917 billions of cubic feet equivalent (bcfe) estimated proved reserves.

Closing Price
$2.50
Day's Change
-0.03 (-1.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.55
Day's Low
2.43
Volume
(Light)
Volume:
305,471

10-day average volume:
484,096
305,471

Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy

8:20 am ET March 3, 2021 (MarketWatch)
Print

Shares of Ocugen Inc. (OCGN) soared 31.0% in premarket trading Wednesday, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%. Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups. "These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States," said Ocugen Chief Executive Shankar Musunuri. "COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19." Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF (IBB) has tacked on 6.8% and the S&P 500 has gained 5.6%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

	

(END) Dow Jones Newswires

March 03, 2021 08:20 ET (13:20 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.